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Summary
The lipopolysaccharide (LPS)-rich outer membrane of
gram-negative bacteria provides a protective barrier
that insulates these organisms from the action of nu-
merous antibiotics. Breach of the LPS layer can there-
fore provide access to the cell interior to otherwise
impermeant toxic molecules and can expose vulnera-
ble binding sites for immune system components
such as complement. Inhibition of LPS biosynthesis,
leading to a truncated LPS molecule, is an alternative
strategy for antibacterial drug development in which
this vital cellular structure is weakened. A significant
challenge for in vitro screens of smallmolecules for in-
hibition of LPS biosynthesis is the difficulty in access-
ing the complex carbohydrate substrates. We have
optimized an assay of the enzymes required for LPS
heptose biosynthesis that simultaneously surveys
five enzyme activities by using commercially available
substrates and report its use in a small-molecule
screen that identifies an inhibitor of heptosesynthesis.
Introduction
Gram-negative bacteria are growing as very important
pathogens in the face of increasing antibiotic resistance.
In particular, the emergence and dissemination of ex-
tended spectrum b-lactamases conferring resistance
to all b-lactam antibiotics in gram-negative bacteria
such as Pseudomonas aeruginosa, Stenotrophomonas
maltophilia, species of Acinetobacter, and the Entero-
bacteriaceae [1, 2] have vaulted these previously con-
trollable microbes to the status of extremely problematic
pathogens in the same league as vancomycin-resistant
gram-positive bacteria [3, 4]. Thus, there is a real clinical
need for new therapeutic strategies that selectively tar-
get gram-negative organisms.
Gram-negative bacteria differ from their gram-posi-
tive counterparts in the presence of a relatively imper-
meable asymmetric outer membrane consisting of an
outer leaflet of lipopolysaccharide (LPS) and an inner
*Correspondence: wrightge@mcmaster.caleaflet of phospholipid. The LPS layer consists of lipid
A (a disaccharyl-lipid complex), a core oligosaccharide,
and a repeating saccharide O-antigen (Figure 1) [5]. The
core oligosaccharide can be subdivided into an inner
core made of 3-deoxy-D-manno-oct-2-ulosonic acid
(Kdo) and heptose residues and an outer core com-
prising hexoses and 2-acetoamido-2-deoxy-hexoses.
Blockade of lipid A and Kdo biosynthesis is lethal for
bacterial growth in the laboratory, while defects in the
biosynthesis of heptoses results in a dramatic reduction
of virulence and increased antibiotic susceptibility [6].
Opportunities to develop chemical strategies that mod-
ulate LPS biosynthesis are beneficial both as research
tools to study the assembly of LPS, but also as novel
antibacterial agents that can either reduce virulence or
potentiate antimicrobial properties of antibiotics pres-
ently not used for gram-negative bacterial infections.
Therefore, small-molecule inhibitors of LPS biosyn-
thesis have the potential to be developed into antimicro-
bial agents themselves or as codrug formulations with
antibiotics.
Despite this promise, there have been relatively few
forays into the development of inhibitors of LPS biosyn-
thetic enzymes, with the exception of the lipid A biosyn-
thetic enzyme LpxC [7–9]. One reason for this lack of ef-
fort is the structural variability of the LPS within bacterial
genera and species. However, the inner core and lipid A
biosynthetic enzymes are generally conserved across
genera and as a result are predicted to be profitable tar-
gets. Another challenge is the chemical complexity and
the unavailability of the substrates of these enzymes for
assays of activity.
The biosynthesis of the nucleotide-activated heptose
precursors for the inner core assembly has been eluci-
dated genetically and biochemically [6, 10–12]. In Es-
cherichia coli, the first step in this pathway is the synthe-
sis of sedoheptulose-7-phosphate, catalyzed by the
transketolase TktA, followed by ketose-aldose isomeri-
zation to D-glycero-b-D-manno-heptose-7-phosphate
by the LPS-dedicated enzyme GmhA (Figure 1). The
sugar is then phosphorylated at the anomeric hydroxyl,
trapping the product in the a configuration and generat-
ing the 1,7-bisphosphate intermediate. This reaction is
catalyzed by an ATP-dependent kinase, HldE, that in
E. coli is fused in a bifunctional enzyme with a down-
stream adenylyltransferase activity in the pathway.
Dephosphorylation at position 7 by the phosphatase
GmhB is followed by the second activity of HldE, ade-
nylylation of the 1-phosphosugar to generate ADP-D-
glycero-b-D-manno-heptose (Figure 1). Inversion of the
D-stereochemistry at C6 generates the final LD-ADP-
activated heptose that is a substrate for specific hepto-
syltransferases involved in the assembly of the LPS core.
Inactivation of the associated genes encoding hep-
tose biosynthesis and transferase enzymes results in
increased bacterial sensitivity to antibiotics and loss of
virulence [10, 13–16]. Therefore, small-molecule inhibi-
tors of enzymes in this pathway could be leads in the de-
velopment of novel antibiotics. The challenge in this ap-
proach is securing sufficient quantities of substrates for
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438Figure 1. The Bacterial Outer Membrane and the Heptose Biosynthetic Pathway
(A) Cartoon representation of the cell envelope of gram-negative bacteria consisting of an asymmetric bilayer of phospholipid and LPS. LPS
contains several conserved components, including lipid A, Kdo, and heptose.
(B) Biosynthesic pathway of activated heptose for incorporation into LPS in E. coli.the enzymes for screening purposes. Here, we report an
in vitro assay that overcomes the substrate accessibility
barrier by recapitulating the biosynthetic pathway
in vitro by using commercially available substrates to
prime the assay. The utility of the assay is demonstrated
in a screen of 1000 small molecules that identifies the
first inhibitor of a heptose biosynthetic enzyme.
Results and Discussion
The biochemical study of ADP-heptose biosynthesis has
been hampered by the lack of readily available sub-
strates of the enzyme-catalyzed reactions. A large-scale
screening campaign for inhibitors of any of these
enzymes would require access to milligram to gramquantities of these rare carbohydrate substrates. We
reasoned that a high-throughput screening assay by-
passing the requirement for these substrates could be
established by reconstituting the four enzymes and five
enzymatic transformations of E. coli D,D-heptose bio-
synthesis in vitro. In this approach, the reaction is
initiated with the readily available precursor sugars fruc-
tose-6-phosphate and ribose-5-phosphate in the pres-
ence of ATP. Flux through the pathway is monitored by
the release of inorganic phosphate (readily visualized
colorimetrically with nmol sensitivity) as a result of the
activity of the penultimate phosphatase reaction cata-
lyzed by GmhB, and by the addition of pyrophosphatase
to cleave pyrophosphate generated in the final step of
ADP-heptose formation catalyzed by the adenylyltrans-
ferase activity of HldE (Figure 2).
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439To explore this proposal, the enzymes TktA, GmhA,
HldE, and GmhB were overexpressed as hexa-His-
tagged constructs in E. coli and purified (Figure 2). The
enzymes were then coincubated initially at 500 ng levels
in buffer and in the presence of 1 mM substrates to con-
firm substrate-dependent phosphate formation by using
the endpoint phosphomolybdate-malachite green de-
tection method [17]. The levels of enzymes were then
lowered in step-wise fashion to achieve a linear depen-
dence of phosphate release over 10 min.
With these conditions, we next determined the appar-
ent Km of ATP in the assay. The reconstituted pathway
uses two equivalents of ATP at the kinase and adenylyl-
transferase steps, both catalyzed by a separate active
site on the bifunctional HldE [16]. Varying ATP concen-
tration resulted in the determination of an apparent Km
of 0.15 mM, which is a composite of both ATP-requiring
steps. To identify competitive inhibitors of these ATP-
dependent enzymes, we maintained ATP concentration
at this level for all additional assays studies. Also, to en-
sure that the flux of substrates through the recapitulated
biochemical pathway was sensitive to each enzymatic
step, the level of each enzyme was systematically varied
to enable the identification of inhibitors of each step
(Figure 3). Because the screen was performed with
concentrations of fructose-6-phosphate and ribose-5-
phosphate that exceeded the Km, we did not rigorously
tune the concentration of TktA; nonetheless, the assay
Figure 2. Overexpression of the Enzymes Required for the Biosyn-
thesis of ADP-D-Glycero-b-D-Manno-Heptose
Lanes 1 and 4, molecular weight standards; lane 2, transketolase
TktA; lane 3, phosphoheptose isomerase GmhA; lane 5, bifunc-
tional kinase/adenylyltransferase HldE; lane 6, phosphatase GmhB.remains quite sensitive to inhibition of this enzyme
(Figure 3).
The ability of this reconstituted biosynthetic pathway
assay to identify inhibitors of a component enzyme was
next validated with the nonhydrolyzable ATP analog b,g-
methyleneadenosine 50-triphosphate, which was pre-
dicted to inhibit HldE kinase activity. This molecule in-
hibited the reaction with an IC50 of 5 mM, demonstrating
that the assay could identify inhibitors of component
enzymes.
To extend this strategy to high throughput, we opti-
mized the assay by using an automated BioMek FX
(Beckman) system. Under these conditions, a Z0 statistic
of 0.7 was determined, indicating that the assay was ro-
bust and adequate for screening [18]. We next per-
formed a screen against 1000 synthetic small molecules
with protein kinase inhibitor templates at 50 mM in
duplicate (Figure 4). The screen identified a compound
Figure 3. Validation of the In Vitro ADP-D-Glycero-b-D-Manno-
Heptose Biosynthetic Pathway Assay
The in vitro assay was designed such that decreasing the amount
of any enzyme in the pathway would result in reduced phosphate
production, as detected at 660 nm by using the malachite green
phosphate detection assay. Reactions were performed in duplicate
with TktA (solid, black bar), GmhA (gray-scale bar), HldE (hatched
bar), and GmhB (white bar) at 32 pmol, 2.1 nmol, 12 pmol, and
2.5 pmol, respectively, as 100% enzyme amount (also used as
the positive control). Each enzyme was systematically analyzed
by lowering the amount of one enzyme while keeping the other
three enzymes at constant amounts. The error bars represent the
spread between two data points.Figure 4. High-Throughput Screening of 1000 Small Molecules against the ADP-D-Glycero-b-D-Manno-Heptose Biosynthetic Pathway
Residual activity (%) duplicate values for each compound are plotted on opposite axes. Duplicates are considered to be in agreement if they
fall on a line through the origin with a slope of 1 (red, dashed line). The positions of the structurally related compounds 1, 2, and 3, are shown on
the graph.
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440(1, 2-methyl-6-methylamino-7-oxo-7H-naphtho[1,2,3-de]
quinoline-4-sulfonic acid) that reduced pathway activity
byw40%. An analog of this hit, compound 2 (6-hydroxy-
7-oxo-7H-benzo[e]perimidine-4-sulfonic acid), showed
w20% inhibition, while compound 3 (4-amino-2-
methyl-naphtho[1,2,3-de]quinolin-7-one), was not an in-
hibitor, suggesting that the sulfonic acid moiety was
likely important for activity.
To identify the enzymatic activity blocked by com-
pound 1, the reaction components of assays performed
in the presence and absence of the compound were sep-
arated by reverse-phase HPLC while monitoring the
Figure 5. Characterization of Inhibitory Properties of Compound 1
(A) Paired-Ion Chromatographic analysis of the effects of com-
pound 1 on the production of ADP-D-glycero-b-D-manno-heptose.
Trace A, ATP control. Trace B, complete reaction after 10 min of in-
cubation. Trace C, complete reaction with 500 mM compound 1.
(B) Double reciprocal plot of effect of increasing concentration of
compound 1 on HldE activity. The Ki for 1 is 63 6 8 mM.absorbance at 254 nm. This reports on the presence of
the adenine group and therefore is a direct measure
of ADP-D-glycero-b-D-manno-heptose production and
consumption of ATP. In the absence of 1, the reaction
mixture contains residual substrate ATP, product ADP
from the HldE kinase activity, and ADP-D-glycero-b-D-
manno-heptose (Figure 5). The distribution of peak areas
of ATP:ADP:ADP-D-glycero-b-D-manno-heptose in the
absence of inhibitor is 4:3:3. If 1 blocked either GmhB
or the adenylyltransferase activity of HldE, the ATP:ADP
ratio should approximate that found in the absence of in-
hibitor. On the other hand, if 1 inhibits TktA, GmhA, or the
kinase activity of HldE, the levels of ATP would be much
more significant than in the absence of inhibitor. In the
presence of compound 1, the ratio of ATP:ADP:ADP-D-
glycero-b-D-manno-heptose is 8:1:1, indicating that
TktA, GmhA, or the kinase activity of HldE are the targets.
We eliminated TktA and GmhA as targets by increas-
ing the levels of these enzymes up to 5-fold each, and we
saw no change in IC50. By using an excess of TktA and
GmhA to produce the HldE kinase substrate D-glyc-
ero-b-D-manno-heptose-7-phospate in situ and the ca-
nonical pyruvate kinase/lactate dehydrogenase couple
to measure ADP production, we determined that 1 is
a competitive inhibitor of the HldE kinase and has a Ki
of 63 6 8 mM (Figure 5). This confirmed that HldE kinase
was the target of 1, and that this compound is the first
reported inhibitor of a heptose biosynthetic enzyme.
Significance
Our results demonstrate for thefirst time that ADP-hep-
tose biosynthesis is a tractable target for high-through-
put screening of inhibitors of LPS biosynthesis. This
assay uses readily available substrates and overex-
pressed enzymes to enable probing of an important
biochemical pathway that otherwise would be highly
challenging to study. By carefully optimizing the assay
in vitro, the identification of novel inhibitors of enzyme
function is possible, and, thus, there is potential to ad-
vance antibiotic research. The utility of the assay was
demonstrated by the identification of the first inhibitor
of heptose biosynthesis. This research opens the
possibility of developing new antimicrobial agents or
adjuvants that act against gram-negative pathogens.
Experimental Procedures
Protein Preparation
The genes encoding TktA, GmhA, GmhB, and HldE were amplified
by PCR from E. coli chromosomal DNA (see the Supplemental Ex-
perimental Procedures available with this article online) and were
cloned into appropriate vectors to create N-terminal His6 fusions.
The amplified genes were sequence verified, and the plasmids
were used to transform E. coli BL21 (DE3), which was used to over-
express each protein. Proteins were purified over immobilized metal
affinity chromatography by using an imidazole gradient. Some pro-
teins were further purified by using a Q Sepharose anion exchange
step. Proteins were analyzed by SDS polyacrylamide gel electro-
phoresis.
Phosphate Detection Assay
One phosphate is released directly by GmhB, and two additional
phosphates are generated after the HldE adenylyltransferase reac-
tion in the presence of pyrophosphatase. Assays were performed
in 96-well plates in the presence of 0.1 U of yeast pyrophosphatase
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441in 20 mM HEPES (pH 8.0), 10 mM MgCl, 10 mM KCl, 1 mM fructose-
6-phosphate, 140 mM ATP, 100 mM thiamine pyrophosphate, 0.1%
Tween 20, 5% dimethylsulfoxide, and purified TktA, GmhA, GmhB,
and HldE in a final volume of 100 ml. The reaction was initiated by
the addition of ribose-5-phosphate (final concentration 1 mM). The
reaction was incubated for 10 min at room temperature and was
quenched by adding 5% trichloroacetic acid at 4ºC. The amount of
phosphate released was measured at 660 nm after the addition of
200 ml of a mixture of ammonium molybdate (4.2%) and malachite
green hydrochloride (0.045%) in 4 M HCl.
Primary Screen
A high-throughput screen of 1000 small molecules from ChemDiv
(San Diego, CA) was performed in 96-well plates in duplicate by us-
ing a Beckman-Coulter Biomek FX Liquid Handler (Fullerton, CA)
and a Molecular Devices SpectraMax Plus384 plate reader (Sunny-
vale, CA). Compounds were dissolved in dimethysulfoxide (w50
mM final concentration) and preincubated with all enzymes and re-
agents except ribose-5-phosphate for 8 min at room temperature.
The reaction was initiated by the addition of ribose-5-phosphate at
1 mM final concentration and was monitored as described above.
Secondary Screen
HldE activity in the presence and absence of compound 1was deter-
mined by coupling the production of ADP with the lactate dehydro-
genase-dependent oxidation of reduced NADH in the presence of
phosphoenol pyruvate (PEP) and pyruvate kinase/lactate dehydro-
genase. The assay mixture was comprised of 0.30 mM NADH, 3
mM PEP, 2.5 U pyruvate kinase, 2.8 U lactate dehydrogenase, 1
mM ribose-5-phosphate and fructose-6-phosphate, 5 nmol GmhA,
0.125 nmol TktA, 300 mM ATP, 20 mM HEPES (pH 8.0), 10 mM
MgCl, and 40 mM KCl to make a 100 ml final volume in 96-well micro-
titer plates. The mixture was incubated in duplicate for 10 min in the
presence of the inhibitor, spanning seven concentrations ranging
from 0.004 to 1.5 mM. The reaction was initiated by the addition of
300 mM ATP, and the oxidation of NADH was monitored at 340 nm.
Data were fit to the four-parameter Equation 1 by using GraFit [19]
to calculate the IC50 value:
y =
A2D
1 + ðI=IC50ÞS
+ D; (1)
where A = minimum response plateau, D = maximum response pla-
teau, I = concentration of inhibitor, and S = slope factor. The Ki value
and mode of inhibition were determined by using the same ADP as-
say under identical conditions. Briefly, seven ATP concentrations,
ranging from 0.04 to 2.5 mM, were used with four compound 1 con-
centrations, ranging from 0.004 to 5 mM. The mode of inhibition was
assessed by visualization of double reciprocal plots and was statis-
tically supported by application of the F-test. The Ki for competitive
inhibition was determined by the fitting of Equation 2 by using GraFit
[19] software:
n=VmaxS=ðKm½1 + I=Kis + SÞ: (2)
Supplemental Data
Supplemental Data including details of oligonucleotide primers are
available at http://www.chembiol.com/cgi/content/full/13/4/437/
DC1/.
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